Intriguingly, representative DLBCL cell lines with mutated p53 are more sensitive to p65 shRNA targeting approach as compared to a cell line with wild-type p53, opposite the prognostic effects observed in the DLBCL study cohort. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.